Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betahistine for motion sickness
NL-OMON32365Phase 2Not yet recruiting
- Sponsor
- TNO
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of betahistine in motion sickness (2 arms), sponsored by TNO. Primary endpoints: Exposure duration until moderate nausea or 30 minutes and Severity or intensity of motion sickness. Planned start Apr 2008; status: not yet recruiting.
02
Drugs
betahistine
03
Conditions
motion sickness
Beyond the preview
Go deeper on NL-OMON32365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32365.